Amelioration of Murine Passive Immune Thrombocytopenia by IVIg and a Therapeutic Monoclonal CD44 Antibody Does Not Require the Myd88 Signaling Pathway

PLoS ONE - United States
doi 10.1371/journal.pone.0071882
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

IVIg Inhibits Reticuloendothelial System Function and Ameliorates Murine Passive-Immune Thrombocytopenia Independent of Anti-Idiotype Reactivity

British Journal of Haematology
Hematology
2001English

Autoimmunity Stimulated by Adoptively Transferred Dendritic Cells Is Initiated by Both and T Cells but Does Not Require MyD88 Signaling

Journal of Immunology
AllergyImmunology
2007English

The Therapeutic Monoclonal Antibody Market

mAbs
AllergyImmunology
2015English

Conversion of a Murine Monoclonal Antibody A13 Targeting Epidermal Growth Factor Receptor to a Human Monoclonal Antibody by Guided Selection

Experimental and Molecular Medicine
BiochemistryMedicineClinical BiochemistryMolecular BiologyMolecular Medicine
2012English

Production and Characterization of a Peptide-Based Monoclonal Antibody Against CD44 Variant 6

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
AllergyImmunology
2015English

Immunotherapy of Hepatoma With a Monoclonal Antibody Against Murine Endoglin

World Journal of Gastroenterology
MedicineGastroenterology
2007English

The Word-Superiority Effect Does Not Require a T-Scope

Perception & Psychophysics
1992English

Drosophila MyD88 Is an Adapter in the Toll Signaling Pathway

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2001English

Persistent Heparin-Induced Thrombocytopenia Treated With IVIg

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy